Mach7 Technologies logs $27.9M full year revenue
- Mach7 Technologies reported FY26 total revenue of $27.9 million, down 17% year-on-year.
- The company's share price rose 1.82% following the financial announcement.
- Growth strategies centre on expanding subscription revenue and executing a cost restructuring plan.
Healthcare software provider Mach7 Technologies (ASX:M7T) reported a 17% drop in total annual revenue to $27.9 million due to fewer one-off capital licence sales.
The lower full-year result was partially offset by a second-half recovery, with revenue rising to $14.3 million compared to $13.7 million in the first half.
"We transformed the business and renewed our leadership team, introducing fresh perspectives and expertise. We also expanded our product suite, restructured our cost base and revenue mix, and established a market-leading customer engagement model," said Mach7 Technologies CEO and Managing Director Teri Thomas.
Operating expenditures declined 16% to $26.7 million through cost restructuring, while recurring revenue of $23.4 million covered 88% of operating expenses.
Management expects recent cost adjustments and contract deployments to support future scalable operations.
Following the announcement, the Mach7 Technologies share price was up at $0.28.
The enterprise software provider generates income primarily through subscription licences, maintenance contracts, and professional support services for healthcare networks.
